Navigation Links
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
Date:9/17/2013

and strategic partnership activities in key international markets.  In terms of the U.S. market, we already began enrollment for our FDA-intended MASTER II trial.  And as we expand our current clinical activities for the Coronary market, we continue to bolster our product pipeline with advances for the Carotid and Peripheral Vasculature target indications," concluded Mr. Milinazzo.

Operational Overview  In fiscal year 2013, the Company announced superior results from the MASTER trial for its MGuard Embolic Protection Stent (EPS).The findings show the novel MGuard EPS provides a significant acute advantage in reducing ST segment elevation versus traditional bare metal and drug eluting stents. As a result, MGuard may hold the potential to prolong the survival of heart attack victims, as evidenced by the 30-day and 6-month data. 

The MASTER trial is an important study for InspireMD, as it is the first large, randomized clinical trial for the MGuard to date. As such, the results have gained much more credence among those in the medical community. The 12-month follow up results for the MASTER trial, scheduled to be released on October 29th, are expected to be an important data point for physicians evaluating the MGuard, as the first year is an important period for evaluating a patient that has received a stent during a heart attack. 

The results disclosed thus far from the MASTER trial have allowed the Company to begin the transition to a new commercial strategy in countries where the MGuard has received regulatory clearance.  This includes setting up the support structure for a direct sales team in certain European countries and advancing discussions with new strategic partners.  The Company recently entered into an agreement with Healthlink Europe, a medical device support services and distribution company, to provide logistical and customer support for InspireMD's commercial operations and clinical
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... di Reggio Emilia, the Regional Health Service office for ... Zebra Technologies Corporation (NASDAQ: ZBRA ) wireless ... (WNS) provided by Zebra has allowed staff to ... via mobile computers, contributing to improved patient care with ... and guest Wi-Fi access and enables hospital staff to ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... Corporation (NYSE: SGP ) today reported that interim ... (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent ... virus (HCV) genotype 1. In the lead-in arms ... lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
... Sciences, Inc. (Nasdaq: CALP ), a leading provider of ... from the United States Food and Drug Administration (FDA) on ... screening and characterization assays for biological drugs. , "We were ... platform to a large group of reviewers. We believe the ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:4/27/2015)... Clyde, NC (PRWEB) April 27, 2015 ... residents will conclude a social media campaign to raise ... and developer, Michael Mamas; and Sri Somesvara Temple. Ironically, ... Ridge Mountains of North Carolina, they thought they were ... commit to at least six months of meditation, service ...
(Date:4/27/2015)... 2015 Telematics Berlin is Europe’s biggest ... associations, CE players and the government to discuss the ... the car. This year’s panel on connected car security ... European Commission, is an opportunity to hear and contribute ... European Automotive Security Standard for years to come. ...
(Date:4/27/2015)... Chicago and its seven surrounding counties ... make area communities healthier, more sustainable and more beautiful. ... every five parkway trees likely to soon be destroyed ... this tree “tipping point,” Chicago-area residents are concerned, as ... Morton Arboretum . The Lisle, Illinois-based tree-focused institution’s Talking ...
(Date:4/27/2015)... The global coagulation analyzers market is estimated to ... however, it is expected to witness high growth ... Brazil in the next five years. Growth in ... such as increasing adoption of automated hemostasis instruments ... developments in high-sensitivity point-of-care coagulation analyzers and introduction ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Mount Soma Monks Do Social Media 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... A new study shows obesity may increase the risk ... by researchers at the National Institutes of Health, reveals ... adenocarcinoma than with squamous cell carcinoma. ,The study ... carcinoma, and 307 women without cancer as the control ...
... year, about 12,000 cases of cancer of the larynx are ... will have to have a laryngectomy// - taking away their ... new alternative that's giving patients their voices back. ,For ... no voice. "Some things you do not forget, and that ...
... to prevent bone loss may also help prevent prostate cancer ... United Kingdom indicates oral sodium clodronate may slow the spread ... death. //This is a drug commonly used to prevent bone ... in about 85 percent of men. The researchers recruited 311 ...
... done previously have shown that the hormone could suppress ... would not work in obese people because studies of another ... do a second trial to see if obese people were ... they are. They're just as sensitive as thin people." ...
... to eat healthier. A new study finds whole grains, fruits ... your overall risk of dying. However, the study also reports ... stroke. ,The U.S. Dietary Guidelines for Americans include choosing ... variety of grains daily, especially whole grains. While at least ...
... who suffer from asthma do not meet the right ... activity// of adults with asthma. Knowing if asthma patients ... health professionals in designing fitness programs for asthma patients. ... Prevention conducted a study to look at the physical ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Extra hormone found to cut appetite by a third 2
... compact system provides an ideal solution ... the laboratory, satellite lab and the ... staining method with wedge-smear technology, the ... standardization in a safe enclosed environment. ...
It is a cardio-pulmonary exercise testing device....
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
... feature our internationally-acclaimed algorithm that is ... has a proven record for reliability ... and it's just one of several ... market leader in the stress testing ...
Medicine Products: